Stockscreener 앱 받기
2.56
8.24%
-0.23
시장 영업 전:
2.58
0.02
+0.78%
Inmune Bio Inc 주식(INMB)의 최신 뉴스
INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift - MSN
Earnings call transcript: INmune Bio Q2 2025 reveals wider losses, stock tumbles - Investing.com
Inmune Bio Inc. shares fall 14.69% premarket after missing primary cognitive endpoints in MINDFuL phase 2 trial. - AInvest
INmune Bio August 2025 slides: three-platform strategy shows clinical progress - Investing.com Nigeria
Why Did INmune Bio Plunge 17.56%? Q2 Loss Widens 110% - AInvest
Transcript : INmune Bio, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
INmune Bio Reports Q2 2025 Net Loss of $24.5 Million, Announces CEO Retirement and $19 Million Registered Direct Offering - AInvest
INmune Bio (INMB) Q2 Loss Widens 110% - AOL.com
INmune Bio Inc (INMB) Q2 2025 Earnings Call Highlights: Promisin - GuruFocus
INmune Bio Reports Q2 2025 Results and Strategic Updates - TipRanks
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
INmune Bio Completes Phase I/II Trial for INKmune™ - TipRanks
INmune Bio Inc Reports Q2 EPS of -$0.45, Missing Estimates; Reve - GuruFocus
INmune Bio: Navigating the Crossroads of Clinical Promise and Financial Realities - AInvest
INmune Bio reports Q2 financial results, misses primary endpoints in MINDFuL trial - Investing.com Nigeria
INmune Bio reports Q2 financial results, misses primary endpoints in MINDFuL trial By Investing.com - Investing.com South Africa
INmune Bio Inc. Announces Second Quarter 2025 Results, - GlobeNewswire
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes - Nasdaq
INmune Bio's INKmune Hits End Points in mCR Prostate Cancer Trial - CGTLive®
Inmune Bio Inc. shares fall 1.09% after-hours as ImmunoPrecise Antibodies Ltd. reports earnings miss and auditor raises 'going concern' doubt. - AInvest
Inmune Bio Q2 Earnings Preview: Consensus EPS Estimate at -$0.38 - AInvest
INmune Bio Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
INmune Bio stock holds steady as Raymond James reiterates Market Perform - Investing.com
INmune Bio Shares Surge as Prostate Cancer Trial Achieves Key Goals - MSN
INmune Bio’s Promising Phase 2 MINDFuL Trial Results Set to Stir Alzheimer’s Market - StocksToTrade
INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints - TipRanks
INmune Bio rises as prostate cancer therapy meets trial goals - TradingView
INmune Bio’s Future: Buying, Holding, or Selling? - timothysykes.com
INmune Bio gains as trial for prostate cancer therapy succeeds - Seeking Alpha
Volume Profile Shows Strong Base for INmune Bio Inc.Target Return Focused Trade Insights Shared - metal.it
INmune Bio Stock Soars 25.78% on Pipeline Advancements - AInvest
INmune Bio stock soars after prostate cancer trial meets endpoints By Investing.com - Investing.com Australia
INmune Bio stock soars after prostate cancer trial meets endpoints - Investing.com
INmune Bio's Novel NK Cell Therapy Shows Tumor Reduction in Advanced Prostate Cancer Trial - Stock Titan
When is INmune Bio Inc. stock expected to show significant growthFree Bull & Bear Market Updates - Jammu Links News
Is INmune Bio Inc. stock overvalued or undervaluedBuild wealth faster with expert stock selection - Jammu Links News
Is INmune Bio Inc. a growth stock or a value stockDiscover market opportunities with real-time data - Jammu Links News
How does INmune Bio Inc. compare to its industry peersUnlock powerful stock screening techniques - Jammu Links News
What institutional investors are buying INmune Bio Inc. stockBuild wealth faster with disciplined trading - Jammu Links News
What are the technical indicators suggesting about INmune Bio Inc.Build wealth with long-term growth strategies - Jammu Links News
How does INmune Bio Inc. generate profit in a changing economyConsistent triple-digit returns - Jammu Links News
What analysts say about INmune Bio Inc. stockTremendous gains - Jammu Links News
What are analysts’ price targets for INmune Bio Inc. in the next 12 monthsExplosive wealth accumulation - Jammu Links News
Published on: 2025-08-03 15:38:34 - Jammu Links News
What makes INmune Bio Inc. stock price move sharplyUnlock powerful trading alerts for success - Jammu Links News
What is INmune Bio Inc. company’s growth strategyAccelerated wealth building - Jammu Links News
What catalysts could drive INmune Bio Inc. stock higher in 2025Get expert insights on market-moving stocks - Jammu Links News
What drives INmune Bio Inc. stock priceDouble-digit growth - Jammu Links News
Is it the right time to buy INmune Bio Inc. stockFinancial News Planner Backed By Experts - jammulinksnews.com
INmune Bio Inc. May Be Forming Higher Low — Chartwatchers AlertReal Trader Watchlist of Hot Stocks Released - metal.it
0.24%
3.39%
자본화:
|
볼륨(24시간):